Lipid-lowering therapy is one major cornerstone of medical treatment of cardiovascular disease in order to modulate atherosclerosis. Statins, ezetimibe and novel PCSK9-inhibitors are already recommended in current guidelines and were shown to improve lipid profiles and have positive effects on the rate of ischemic events and cardiovascular mortality. Recent studies suggest that the concept of “The lower the better” might be valid at least regarding low density lipoproteins. In addition, lowering lipoprotein (a) still displays a major challenge in lipid therapy. Furthermore, also lowering triglycerides seems to improve cardiovascular outcome. Regarding triglycerides, icosapent ethyl, a polyunsaturated fatty acid recently attracted attention showing cardiovascular risk reduction due to triglyceride lowering. Therefore, new therapeutic strategies and drug classes are eagerly awaited. Targeting LDL, bempedoic acid and the siRNA inclisiran provide promising results. Moreover, regarding TG a monoclonal antibody called evinacumab and an antisense-oligonucleotide against ANGPTL3 showed effective TG-lowering. At least, using antisense-oligonucleotides against ApoC-III and Lp(a) resulted in promising outcomes. In this review, current and future options for lipid management are presented depending on different drug classes.

为了调节动脉粥样硬化，降脂治疗是心血管疾病医学治疗的主要基石之一。他汀类药物，依泽替米贝和新型PCSK9抑制剂已被推荐用于当前指南中，并被证明可以改善血脂水平，并对缺血事件和心血管疾病的死亡率具有积极作用。最近的研究表明，“越低越好”的概念至少对于低密度脂蛋白可能是有效的。另外，降低脂蛋白（a）仍然在脂质治疗中显示出主要挑战。此外，降低甘油三酸酯似乎也可以改善心血管疾病的预后。关于甘油三酸酯，二十碳五烯酸乙酯，一种多不饱和脂肪酸，最近受到关注，由于甘油三酸酯的降低，降低了心血管疾病的风险。因此，迫切需要新的治疗策略和药物类别。靶向低密度脂蛋白，苯二酸和siRNA inclisiran提供了有希望的结果。此外，关于TG，一种称为evinacumab的单克隆抗体和一种针对ANGPTL3的反义寡核苷酸显示出有效的TG降低。至少，使用针对ApoC-III和Lp（a）的反义寡核苷酸可产生有希望的结果。在这篇综述中，根据不同的药物类别，介绍了当前和未来的脂质管理选择。使用针对ApoC-III和Lp（a）的反义寡核苷酸可产生有希望的结果。在这篇综述中，根据不同的药物类别，介绍了当前和未来的脂质管理选择。使用针对ApoC-III和Lp（a）的反义寡核苷酸可产生有希望的结果。在这篇综述中，根据不同的药物类别，介绍了当前和未来的脂质管理选择。